DBV Technologies S.A. (EPA:DBV)
0.797
-0.011 (-1.36%)
Feb 21, 2025, 5:35 PM CET
DBV Technologies Revenue
DBV Technologies had revenue of $1.07M USD in the quarter ending September 30, 2024, a decrease of -54.81%. This brings the company's revenue in the last twelve months to $12.52M, up 125.54% year-over-year. In the year 2023, DBV Technologies had annual revenue of $15.73M with 224.69% growth.
Revenue (ttm)
$12.52M
Revenue Growth
+125.54%
P/S Ratio
6.83
Revenue / Employee
$119.19K
Employees
105
Market Cap
81.73M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
Dec 31, 2019 | 14.71M | 3.52M | 31.49% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
EssilorLuxottica Société anonyme | 26.51B |
Sanofi | 44.29B |
Sartorius Stedim Biotech | 2.78B |
bioMérieux | 3.81B |
Eurofins Scientific SE | 6.95B |
Ipsen | 3.57B |
Virbac | 1.34B |
emeis Société anonyme | 5.43B |
DBV Technologies News
- 5 weeks ago - Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - GlobeNewsWire
- 2 months ago - DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids - Benzinga
- 2 months ago - DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids - Benzinga
- 2 months ago - Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket - Benzinga
- 2 months ago - DBV stock rallies post-market on FDA Viaskin update - Seeking Alpha
- 2 months ago - DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old - GlobeNewsWire
- 3 months ago - BRAIDWELL LP's Strategic Acquisition in DBV Technologies SA - GuruFocus
- 3 months ago - DBV Technologies Announces Plan to Implement ADS Ratio Change - GlobeNewsWire